• Research and Development

  Potential IPF Therapy PXS-5382A Shows Potential in Phase 1 Trial

  Posted by Pulmonary Fibrosis News Moderator on December 6, 2018 at 11:32 am

  Phase 1 data show that Pharmaxis’ second LOXL2 inhibitor, PXS-5382A, is safe and holds potential to treat fibrotic diseases, including IPF. Click here to find out more.

  Did you know about this potential treatment? What are your thoughts on it?

  Pulmonary Fibrosis News Moderator replied 6 years, 1 month ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply